ARCHIVES

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Don’t Blame FDA For All Problems, Broder Says

September 7, 1990

NIH Forming Special Emphasis Panel To Review Clinical Oncology Grants

September 18, 1998

Pesticides Increase Leukemia Risk, USA Investigations Report

July 17, 1987

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

December 28, 2012

Guest Editorial: Anil Potti Hires “Online Reputation Managers” As Journals Retract His Biomarker Research

April 15, 2011

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014